BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230623
DTSTAMP:20260516T064935
CREATED:20230314T122048Z
LAST-MODIFIED:20230314T122048Z
UID:36825-1687219200-1687478399@www.pharmajournalist.com
SUMMARY:Next Gen Inhalation Delivery Summit
DESCRIPTION:With exciting developments in pioneering inhaled drug products from Moderna\, Vertex\, ReCode Therapeutics\, and Pieris Pharmaceuticals\, now is the time to go full speed ahead on your efforts into inhaled formulation and delivery optimization. Despite the inhalation drug delivery market being expected to reach $18.6 billion by 2029\, achieving cell-specific delivery\, and optimized stability remain vital challenges. \nThis June\, the hotly anticipated Next Gen Inhalation Delivery Summit will debut\, where we will unite 80+ senior leaders at this definitive meeting dedicated to the inhalation community. Whether your work in COPD\, asthma\, IPF\, lung cancer or infectious disease\, this comprehensive forum offers the solution to capitalize on the common goal of targeted lung delivery. \nBe part of the conversation in Boston this June\, where we unpick: \n\nOvercoming pulmonary biological barriers to minimize dosage and maximize therapeutic benefit\nAdvancing your inhalation formulation techniques for improved stability and longer shelf-lives\nEnsuring device-formulation compatibility with patient compliance and patient convenience\n\nWith key speakers from the likes of Janssen\, Avalyn Pharma\, and FDA\, exciting content\, and networking opportunities\, you cannot afford to miss out! \nTo know more visit: https://ter.li/hlg9tw
URL:https://www.pharmajournalist.com/event/next-gen-inhalation-delivery-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230623
DTSTAMP:20260516T064935
CREATED:20230330T101610Z
LAST-MODIFIED:20230330T102722Z
UID:36955-1687219200-1687478399@www.pharmajournalist.com
SUMMARY:2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit
DESCRIPTION:Exciting results are expected this year\, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73\, CD39 and A2AR! \nTo ensure the community can capitalize on this\, the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit will be returning this June (20 – 22) in Boston\, MA – dedicated to bringing together 80+ industry experts to tackle the biggest problems the field continues to face in discovering translating and clinically developing CD73\, CD39\, A2A and A2B focused therapeutics. \nJoin this unmissable 3-day meeting to explore the biology of the receptors and enzymes opening doors to new therapeutic opportunities at the discovery stage\, utilize novel technologies and approaches through translation to clinical development to improve patient selection\, and discover new ways of finding mono and combo therapy approaches to increase potency and safety. \nTop Speakers includes: \n\nAlex Gaither\, Vice president from Exscientia AI – evaluating ways to improve preclinical engineering practices for adenosine mono & combo therapeutics candidates\nChangyun Hu\, CSO from Adept Therapeutics – deep diving into preclinical and clinical Adenosine receptor targeting and more\nJoanne Lager\, Chief Medical Officer from iTeos Therapeutics – looking beyond T Cell and assessing potential outcomes for the Adenosine field in the event of an approval or major failure\n\n& 15+ more expert speakers! \nDownload your copy of the newly released agenda to find everything that will help you translate and clinically develop your adenosine therapeutic: https://ter.li/hende5 \nInterested in speaking? Contact info@hansonwade.com \nInterested in sponsoring? Contact sponsor@hansonwade.com
URL:https://www.pharmajournalist.com/event/2nd-annual-adenosine-pathway-targeted-cancer-immunotherapy-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230621
DTEND;VALUE=DATE:20230623
DTSTAMP:20260516T064935
CREATED:20230309T105108Z
LAST-MODIFIED:20230309T105108Z
UID:36775-1687305600-1687478399@www.pharmajournalist.com
SUMMARY:Antimicrobial Resistance Connect Europe
DESCRIPTION:This event will take place in London on 21-22 June 2023 in London\, focusing on the three biggest priorities enabling growth in the AMR field – Innovation\, Investment & Policy – AMR Connect enables you to foster connections with key stakeholders in anti-microbial research and build actionable next steps to combat the silent pandemic. \n \nAMR Connect provides your team with the opportunity to create actionable steps within an interdisciplinary environment\, creating a unified approach across sectors. The demand to innovate and advance the way we tackle resistance is paramount and commanding the attention of nations globally – book your place now and join us in tackling the silent pandemic. \nBenefits of attending \n\nWith AMR considered one of the top 10 public health threats globally\, uncover how different regions are developing effective policy guidelines and incentive schemes that work for their region – with sessions from ReAct Latin America\, Asia-Europe Foundation\, WHO and many more.\nApply for the Innovation Showcase\, showcasing your state-of-the-art research in drug development\, diagnostics or one health in front of our room of investors\, pharma and solution providers.\nStreamline your route from discovery to market through case studies from Arrepath and Madam Therapeutics on the utilisation of AI/ML to reduce drug development timescales.\nMeet your next partner and foster connections across stakeholders through future-focussed roundtables on the biggest challenges impacting the field – including regulation\, policy and the future of anti-infectives.\n\nTake advantage of the early bird discount ending on 24 March. Book now to SAVE up to £700.
URL:https://www.pharmajournalist.com/event/antimicrobial-resistance-connect-europe/
LOCATION:LONDON\,UK
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR